Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 Study of Orofacial Pain and PropRANOlol
Temporomandibular Disorders
Primary: Change in the Weekly Mean Pain Index After 9 Weeks of Treatment — -13.9; -12.1 units on a scale — p=0.414
Phase 2 N=55 Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
Prostatic Neoplasm
Primary: Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging — 24 Participants
Phase 2 N=40 Gulf War Illness Nasal Irrigation Study
Persian Gulf Syndrome · Chronic Sinusitis · Fatigue
Primary: Change in Sino-Nasal Outcome Test (SNOT-20) Score From Baseline — -16.9; -8.8; -3.4; -18.9 score on a scale
Phase 2 N=125 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Melanoma and Brain Metastases
Primary: Intracranial Response (IR) Rate in Cohort A — 45 Number of participants — p=<.0001
Phase 2 N=66 Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause — 52.6 percentage of patients
Phase 2 N=12 Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Phase 2 N=46 A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
Heart Failure · Decompensated Heart Failure · Acute Heart Failure
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 5; 5; 7 Participants
Phase 2 N=20 Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Diabetic Retinopathy · Macular Edema
Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision. — 8.3; 8.5 ETDRS Letters
Phase 2 N=74 A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
Phase 2 N=501 Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
Atherosclerotic Cardiovascular Disease · Familial Hypercholesterolemia · Diabetes
Primary: Percentage Change in LDL-C From Baseline to Day 180 — 2.1; -27.9; -38.4; -41.9 Percent change — p=<0.0001
Phase 2 N=19 Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large Cell Lymphoma Relapsed/Refractory
Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants
Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Phase 2 N=37 Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Objective Response Rate — 10.8 percentage of participants
Phase 2 N=8 Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Parkinson Disease
Primary: Glutathione (GSH) Brain Levels — 0.93; 0.99 mM